Markets

Sector Update: Health Care

Health-care shares were fairly mixed in pre-market trade Wednesday.

In health-care stocks news, Gilead Sciences ( GILD ) announced its Phase 2 study evaluating simtuzumab in combination with gemcitabine for patients with previously untreated advanced pancreatic cancer failed to meet its primary endpoint of progression-free survival.

Shares of GILD are up $0.73, or 0.70%, at $105.49 in pre-market trading within a 52-week range of $58.81 - $110.64.

And, shareholders of Salix Pharmaceuticals ( SLXP ), a specialty pharmaceutical company, said they want the company to retreat from its proposed acquisition of Cosmo Pharmaceuticals, Reuters reported late Tuesday.

Shares are up 0.46% at $149.40 in the after hours session, with a 52-week range of $65.38 - $162.38.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

GILD

Other Topics

Commodities